Scientists are increasingly investigating retatrutide, a novel drug developed by Eli Lilly, as a potential advance in weight loss . Different than many earlier approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, substances that affect hunger and glucose regulati